Research Article | Volume: 12, Issue: 8, August, 2022

Laboratory optimization of the production of guanidium-based inactivated transport media to support SARS-CoV-2 PCR testing in Indonesia

Shabarni Gaffar Hesti Lina Wiraswati Savira Ekawardhani Lia Faridah Nisa Fauziah Amila Laelalugina Annisa Retno Arimdayu Chanda Taruna Adiarka Utomo Maulana Ihsan Ikhwan Ramadhana Sanny Hafidhoh Siti Nururrohmah Trifanny Nur Azizah Mia Tria Novianti Radewi Safira Fauzia   

Open Access   

Published:  Aug 04, 2022

DOI: 10.7324/JAPS.2022.120808
Abstract

The availability of a viral transport medium (VTM) is often an obstacle to COVID-19 testing, especially for countries that are not VTM producers, including Indonesia. Therefore, the Parasitology Laboratory of Medicinal Faculty, Universitas Padjadjaran, Indonesia, developed an inactivation transport medium called “VITPAD®” that uses a guanidium-based buffer solution. This study evaluated VITPAD® as a transport medium for swab samples and scaled-up production from 2,000 tubes per month to 60,000 per month to support COVID-19 testing in Indonesia. VITPAD® has good stability and sterility, with a lifespan of over 2 years, and it performs well as a transport medium for COVID-19 samples. The production capacity was successfully scaled-up by implementing scheduling and capacity management, with the first large-scale production of VITPAD® distributed to 26 teaching hospitals in Indonesia.


Keyword:     Guanidium-based buffer inactivation transport media polymerase chain reaction production capacity


Citation:

Gaffar S, Wiraswati HL, Ekawardhani S, Faridah L, Fauziah N, Laelalugina A, Arimdayu AR, Utomo CTA, Ihsan M, Ramadhana I, Nururrohmah SHS, Azizah TN, Novianti MT, Fauzia RS. Laboratory optimization of the production of guanidium-based inactivated transport media to support SARS-CoV-2 PCR testing in Indonesia. J Appl Pharm Sci, 2022; 12(08):070–081.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Anderson G, Scott M. Determination of product shelf life and activation energy for five drugs of abuse. Clin Chem, 1991; 37(3):398-402. https://doi.org/10.1093/clinchem/37.3.398

Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci, 2012; 2(3):129-38.

Barone A. 2020. Bottleneck. [ONLINE] Available at: https:// www.investopedia.com/terms/b/bottleneck.asp [Accessed August 2021]

Borkakoty B, Jakharia A, Bali NK, Sarmah MD, Hazarika R, Baruah G, Bhattacharya C, Biswas D. A preliminary evaluation of normal saline as an alternative to viral transport medium for COVID-19 diagnosis. The Indian journal of medical research, 2021, 153(5&6):684-688. https://doi.org/10.4103/ijmr.IJMR_4346_20

Brown S, Bessant J. Lamming R. Strategic operations management. 2nd edition, Elsevier Butterworth-Heinemann, Oxford, UK, 2005.

Chan KH, Sridhar S, Zhang RR, Chu H, Fung AYF, Chan G, Chan JFW, To KKW, Hung IFN, Cheng VCC, Yuen KY. Factors affecting stability and infectivity of SARS-CoV-2.

J Hosp Infect, 2020; 106(2):226-31. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Available via https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/situation-reports/ (Accessed April 2021).

Inactivation Transport Medium (ITM). Product features. Wuxi NEST Biotechnology Co.,Ltd, Jiangsu, China, 2020. Available via https://www. nest-biotech.com/disposable-sampler/59256318.html (Accessed March 2022).

Johnson FB. Transport of viral specimens. Clin Microbiol Rev, 1990; 3(2):120-31. https://doi.org/10.1128/CMR.3.2.120

Kirkland PD, Frost MJ. The impact of viral transport media on PCR assay results for the detection of nucleic acid from SARS-coV-2. Pathology, 2020; 52(7):808-11. https://doi.org/10.1016/j.pathol.2020.09.013

Koenig, DT. Manufacturing engineering: principles for optimization. 2nd edition, Taylor & Francis, Washington, DC, 1994.

Lam F, Moubarak M, Wilson J, Ford B. Preparing viral transport media for COVID-19 testing, 2020 [ONLINE]. Available via https://www. pppmag.com/article/2638 (Accessed April 2021).

Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S, Ammons B, Mahony JB, Smieja M. Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses. J Clin Microbiol, 2011; 49(6):2138-42. https://doi.org/10.1128/JCM.00327-11

McAuley J, Fraser C, Paraskeva E, Trajcevka E, Sait M, Wang N, Bert E, Purcell D, Strugnell R. Optimal preparation of SARS -CoV-2 viral transport medium for culture. Virol J, 2021; 18(53):1-6. https://doi.org/10.1186/s12985-021-01525-z

Monczka RM, Handfield RB, Giunipero LC, Patterson JL. Purchasing and supply chain management. 6th edition, Cencage Learning, Boston, MA, 2016.

Orlicky J. Material requirements planning. McGraw-Hill, New York, 1975.

Petersen J, Dalal S, Jhala D. Criticality of in-house preparation of viral transport medium in times of shortage during COVID-19 pandemic. Lab Med, 2021; 52(2):e39-45. https://doi.org/10.1093/labmed/lmaa099

Smith KP, Cheng A, Chopelas A, DuBois CS, Mezghani I, Rodriguez S, Talay M, Kirby JE. Large-scale, in house production of viral transport media to support SARS-Cov-2 PCR testing in a multihospital health care network during the COVID-19 pandemic. J Clin Microbiol, 2020; 58(8):1-7. https://doi.org/10.1128/JCM.00913-20

Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ, Fernholz E, Boerger A, Schuetz AN, Yao JD, Binnicker MJ. Evaluation of saline, phosphate-buffered saline, and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing. J Clin Microbiol, 2020; 58(6):e00590-20. https://doi.org/10.1128/JCM.00590-20

Van Bockel D, Munier CML, Turville S, Badman SG, Walker G, Stella AO, Aggarwal A, Yeang M, Condylios A, Kelleher AD, Applegate TL, Vallely A, Whiley D, Rawlinson W, Cunningham P, Kaldor J, Guy R. Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in point-of-care (POC) testing. Viruses, 2020; 12(11):1208. https://doi.org/10.3390/v12111208

Wingfield PT. Use of protein folding reagents. Curr Protoc Protein Sci, 2001; Appendix 3:Appendix-3A.

World Health Organization. Target product profiles for priority diagnostics to support response to COVID-19 pandemic v.1.0. R&D Blueprint, Switzerland, 2020.

Article Metrics

2 Absract views 1 PDF Downloads 3 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required